Dr. Bazhenova on the Challenges of Second-Line Therapy in SCLC

EP: 1.Dr. Melosky on the Use of Lurbinectedin in SCLC

Now Viewing

EP: 2.Dr. Bazhenova on the Challenges of Second-Line Therapy in SCLC

EP: 3.Dr. Florez (Duma) on Nihilism in SCLC

EP: 4.Translating Evidence to Clinical Practice to Improve Outcomes in Patients with Small Cell Lung Cancer

Lyudmila A. Bazhenova, MD, medical oncologist, professor of medicine, Moores Cancer Center, University of California San Diego Health, discusses the challenges of second-line therapy in small cell lung cancer (SCLC).

Most patients with SCLC have a lower performance status because they typically have multiple comorbidities, Bazhenova says. Due to lower performance status, some patients will not be fit enough to undergo second-line therapy, Bazhenova explains. 

The emergence of more viable treatment options in the first-line setting could improve the number of patients capable of receiving second-line treatment, Bazhenova continues. By developing more efficacious and tolerable first-line treatments, patients will be more fit when they experience disease progression, Bazhenova concludes.